Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?

Agop Y. Bedikian, Marcella M. Johnson, Carla L. Warneke, Nicholas E. Papadopoulos, Kevin B. Kim, Wen Jen Hwu, Susan McIntyre, Michelle Rohlfs, Jade Homsi, Patrick Hwu

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The aim of this study was to determine the impact of complete response (CR) to systemic therapy on survival. We reviewed the cases of 647 chemo-naive patients with metastatic melanoma who were treated with cisplatin-vinblastine- dacarbazine or cisplatin-taxol-dacarbazine alone, or cisplatin-vinblastine- dacarbazine together with interferon α or interleukin-2 plus interferon α. After excluding patients with uveal melanoma and patients who had resection of metastases, 567 patients were eligible to participate in this analysis. An event chart is presented for the 51 patients with CR and for three random samples of patients without CR. We compared overall survival of responders versus nonresponders using response as a time-dependent covariate in a Cox proportional hazards model. In addition, we used the landmark method, choosing 6 months as the landmark. Logistic regression techniques were used to determine factors associated with CR to therapy. All P values were 2-tailed and considered significant at α less than 0.05. Analyses were conducted using SAS for Windows. In this analysis, CR was associated with patients who were younger, male, and who had better performance status, lower M-stage, no liver metastases, and no visceral sites involved, normal LDH and had received biochemotherapy. While accounting for these factors, the relationship between CR and survival remained statistically significant, suggesting a causal relationship between response and survival. Using 6-month landmark analysis method, we still find a significant difference in overall survival between response groups, favoring patients who achieved CR with systemic therapy. In conclusion, CR to systemic therapy is associated with longterm survival in patients with stage IV melanoma.

Original languageEnglish (US)
Pages (from-to)84-90
Number of pages7
JournalMelanoma Research
Volume21
Issue number1
DOIs
StatePublished - Feb 1 2011

Fingerprint

Melanoma
Survival
Dacarbazine
Cisplatin
Therapeutics
Vinblastine
Interferons
Neoplasm Metastasis
Paclitaxel
Proportional Hazards Models
Interleukin-2
Logistic Models
Liver

Keywords

  • Biochemotherapy
  • Complete response
  • Long-term survival melanoma
  • Systemic therapy

ASJC Scopus subject areas

  • Oncology
  • Dermatology
  • Cancer Research

Cite this

Bedikian, A. Y., Johnson, M. M., Warneke, C. L., Papadopoulos, N. E., Kim, K. B., Hwu, W. J., ... Hwu, P. (2011). Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival? Melanoma Research, 21(1), 84-90. https://doi.org/10.1097/CMR.0b013e328341445f

Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival? / Bedikian, Agop Y.; Johnson, Marcella M.; Warneke, Carla L.; Papadopoulos, Nicholas E.; Kim, Kevin B.; Hwu, Wen Jen; McIntyre, Susan; Rohlfs, Michelle; Homsi, Jade; Hwu, Patrick.

In: Melanoma Research, Vol. 21, No. 1, 01.02.2011, p. 84-90.

Research output: Contribution to journalArticle

Bedikian, AY, Johnson, MM, Warneke, CL, Papadopoulos, NE, Kim, KB, Hwu, WJ, McIntyre, S, Rohlfs, M, Homsi, J & Hwu, P 2011, 'Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?', Melanoma Research, vol. 21, no. 1, pp. 84-90. https://doi.org/10.1097/CMR.0b013e328341445f
Bedikian, Agop Y. ; Johnson, Marcella M. ; Warneke, Carla L. ; Papadopoulos, Nicholas E. ; Kim, Kevin B. ; Hwu, Wen Jen ; McIntyre, Susan ; Rohlfs, Michelle ; Homsi, Jade ; Hwu, Patrick. / Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?. In: Melanoma Research. 2011 ; Vol. 21, No. 1. pp. 84-90.
@article{db751612d0b246c8a683ae65fa1d3c0d,
title = "Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?",
abstract = "The aim of this study was to determine the impact of complete response (CR) to systemic therapy on survival. We reviewed the cases of 647 chemo-naive patients with metastatic melanoma who were treated with cisplatin-vinblastine- dacarbazine or cisplatin-taxol-dacarbazine alone, or cisplatin-vinblastine- dacarbazine together with interferon α or interleukin-2 plus interferon α. After excluding patients with uveal melanoma and patients who had resection of metastases, 567 patients were eligible to participate in this analysis. An event chart is presented for the 51 patients with CR and for three random samples of patients without CR. We compared overall survival of responders versus nonresponders using response as a time-dependent covariate in a Cox proportional hazards model. In addition, we used the landmark method, choosing 6 months as the landmark. Logistic regression techniques were used to determine factors associated with CR to therapy. All P values were 2-tailed and considered significant at α less than 0.05. Analyses were conducted using SAS for Windows. In this analysis, CR was associated with patients who were younger, male, and who had better performance status, lower M-stage, no liver metastases, and no visceral sites involved, normal LDH and had received biochemotherapy. While accounting for these factors, the relationship between CR and survival remained statistically significant, suggesting a causal relationship between response and survival. Using 6-month landmark analysis method, we still find a significant difference in overall survival between response groups, favoring patients who achieved CR with systemic therapy. In conclusion, CR to systemic therapy is associated with longterm survival in patients with stage IV melanoma.",
keywords = "Biochemotherapy, Complete response, Long-term survival melanoma, Systemic therapy",
author = "Bedikian, {Agop Y.} and Johnson, {Marcella M.} and Warneke, {Carla L.} and Papadopoulos, {Nicholas E.} and Kim, {Kevin B.} and Hwu, {Wen Jen} and Susan McIntyre and Michelle Rohlfs and Jade Homsi and Patrick Hwu",
year = "2011",
month = "2",
day = "1",
doi = "10.1097/CMR.0b013e328341445f",
language = "English (US)",
volume = "21",
pages = "84--90",
journal = "Melanoma Research",
issn = "0960-8931",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?

AU - Bedikian, Agop Y.

AU - Johnson, Marcella M.

AU - Warneke, Carla L.

AU - Papadopoulos, Nicholas E.

AU - Kim, Kevin B.

AU - Hwu, Wen Jen

AU - McIntyre, Susan

AU - Rohlfs, Michelle

AU - Homsi, Jade

AU - Hwu, Patrick

PY - 2011/2/1

Y1 - 2011/2/1

N2 - The aim of this study was to determine the impact of complete response (CR) to systemic therapy on survival. We reviewed the cases of 647 chemo-naive patients with metastatic melanoma who were treated with cisplatin-vinblastine- dacarbazine or cisplatin-taxol-dacarbazine alone, or cisplatin-vinblastine- dacarbazine together with interferon α or interleukin-2 plus interferon α. After excluding patients with uveal melanoma and patients who had resection of metastases, 567 patients were eligible to participate in this analysis. An event chart is presented for the 51 patients with CR and for three random samples of patients without CR. We compared overall survival of responders versus nonresponders using response as a time-dependent covariate in a Cox proportional hazards model. In addition, we used the landmark method, choosing 6 months as the landmark. Logistic regression techniques were used to determine factors associated with CR to therapy. All P values were 2-tailed and considered significant at α less than 0.05. Analyses were conducted using SAS for Windows. In this analysis, CR was associated with patients who were younger, male, and who had better performance status, lower M-stage, no liver metastases, and no visceral sites involved, normal LDH and had received biochemotherapy. While accounting for these factors, the relationship between CR and survival remained statistically significant, suggesting a causal relationship between response and survival. Using 6-month landmark analysis method, we still find a significant difference in overall survival between response groups, favoring patients who achieved CR with systemic therapy. In conclusion, CR to systemic therapy is associated with longterm survival in patients with stage IV melanoma.

AB - The aim of this study was to determine the impact of complete response (CR) to systemic therapy on survival. We reviewed the cases of 647 chemo-naive patients with metastatic melanoma who were treated with cisplatin-vinblastine- dacarbazine or cisplatin-taxol-dacarbazine alone, or cisplatin-vinblastine- dacarbazine together with interferon α or interleukin-2 plus interferon α. After excluding patients with uveal melanoma and patients who had resection of metastases, 567 patients were eligible to participate in this analysis. An event chart is presented for the 51 patients with CR and for three random samples of patients without CR. We compared overall survival of responders versus nonresponders using response as a time-dependent covariate in a Cox proportional hazards model. In addition, we used the landmark method, choosing 6 months as the landmark. Logistic regression techniques were used to determine factors associated with CR to therapy. All P values were 2-tailed and considered significant at α less than 0.05. Analyses were conducted using SAS for Windows. In this analysis, CR was associated with patients who were younger, male, and who had better performance status, lower M-stage, no liver metastases, and no visceral sites involved, normal LDH and had received biochemotherapy. While accounting for these factors, the relationship between CR and survival remained statistically significant, suggesting a causal relationship between response and survival. Using 6-month landmark analysis method, we still find a significant difference in overall survival between response groups, favoring patients who achieved CR with systemic therapy. In conclusion, CR to systemic therapy is associated with longterm survival in patients with stage IV melanoma.

KW - Biochemotherapy

KW - Complete response

KW - Long-term survival melanoma

KW - Systemic therapy

UR - http://www.scopus.com/inward/record.url?scp=79952747501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952747501&partnerID=8YFLogxK

U2 - 10.1097/CMR.0b013e328341445f

DO - 10.1097/CMR.0b013e328341445f

M3 - Article

C2 - 21102360

AN - SCOPUS:79952747501

VL - 21

SP - 84

EP - 90

JO - Melanoma Research

JF - Melanoma Research

SN - 0960-8931

IS - 1

ER -